Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Diamond Capital Management is dedicated to offering clients well managed alternative investment products that offer consistent returns and protection of principal achieved through the proper application of money management and continuous evaluation of risk exposure. The principals at Diamond Capital have a solid understanding of the markets and the instruments utilized in the strategies. Past experience has demonstrated that using modifications of tried and true concepts such as proper portfolio diversification, diligent adaptation to market volatility, dollar-cost-averaging with judicious profit taking throughout the investment term, among others, hold the most promise. Our success is measured against other investment benchmarks, as well as peer group and related industry benchmarks. While short-term performance is always difficult to predict, our long-term goal is to provide consistently attractive returns, within reasonable risk parameters. In doing so, we at Diamond Capital take personal pride in managing accounts with our clients&s; best interest in mind. Diamond Capital Management, LLC, ("DCM") is registered with the Commodity Futures Trading Commission ("CFTC") as a Commodity Trading Advisor ("CTA") and is a member of the National Futures Association ("NFA"). We invite you to investigate Diamond&s;s strategies further and discover a non-correlated alternative investment products to compliment your long term investment goals. To learn more about Diamond Capital and the potential value DCM can add to your overall portfolio, please explore our site, or contact us directly. Past performance is not necessarily a representation of future results. Alternative investments such as managed futures investments are speculative, involve substantial risk, and are not suitable for all investors.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2010 | CytoPherx | Series B | 11.7M |
2/2004 | NeurogesX | Series C | 35M |
3/2004 | TransMolecular | Series C | 0 |
6/2010 | CytoPherx | Series B | 0 |
3/2004 | TransMolecular | Series C | 0 |
2/2004 | NeurogesX | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|